Articles related to DRUG DISCOVERIES & DEVELOPMENT

ALK7 gives pancreatic cancer cells both the engine to move and the tools to invade…But if we can inhibit ALK7 at the cancer’s earliest and most vulnerable stage, we might see better outcomes for patients.

In a significant advancement for knee osteoarthritis treatment, LEVI-04 demonstrated pain reduction in more than 50% of treated patients, with effects lasting through 20 weeks of study.

Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.

The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.

A phase 3 trial demonstrates that aficamten improves oxygen utilization during exercise for obstructive HCM patients, indicating its potential to enhance daily functionality and quality of life.